Genomics Law Report
FDA action against 23andMe doesn’t signal the end for personal genomics
Many have speculated that the FDA action against 23andMe spells an end for personal genomics. But according to a new ...
Is the ‘designer baby’ debate more about gene patentability?
The controversial "designer baby" debate speaks to the larger issues about patent eligibility and the patent application process, according to ...
Genetic testing service deCODEme shutting down in wake of Amgen/deCODE deal
After the $415 million sale of deCODE Genetics to Amgen, deCODE's deCODEme direct-to-consumer genomic screening service will be shut down ...
Amgen buys deCODE: What are the implications for genetic testing customers?
The big biotech news of the day is the $415 million sale of deCODE Genetics to Amgen. Coverage of the ...
